Current report No. 21\/2022<\/p>\n\n\n\n
Date prepared: 15\/07\/2022<\/p>\n\n\n\n
Abbreviated name of the issuer: CELON PHARMA S.A.<\/p>\n\n\n\n
Subject: Admission and introduction of 5,000 ordinary C-series bearer shares of the Company to stock exchange trading<\/p>\n\n\n\n
Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering \u2013 current and periodical information<\/p>\n\n\n\n
Content of the report:<\/p>\n\n\n\n
The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby announces that on July 15, 2022 the Management Board of the Warsaw Stock Exchange (\u201cWSE\u201d) has adopted a resolution concerning the admission and introduction of the Company\u2019s ordinary C-series bearer shares to stock exchange trading on the GPW Main Market List.<\/p>\n\n\n\n
In its resolution, the Warsaw Stock Exchange Management Board stated that pursuant to \u00a7 19.1 and \u00a7 19.2 of the WSE Rules, 5,000 ordinary C-series bearer shares of the Company, having the nominal value of PLN 0.10 each, designated with the \u201cPLCLNPH00015\u201d code by the Central Securities Depository of Poland, are admitted to stock exchange trading on the primary market.<\/p>\n\n\n\n
The GPW Management Board decided to introduce the above-mentioned shares of the Company to trading on the primary market as of July 22, 2022, subject to the assimilation of these shares with the shares in the exchange trade, designated with the \u201cPLCLNPH00015\u201d code, by the Central Securities Depository of Poland on July 22, 2022.<\/p>\n","protected":false},"excerpt":{"rendered":"